Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development

Health Catalyst Launches
COVID-19 Patient Data
Repository to Speed
Vaccine Development

© 2020 Health Catalyst
Proprietary. Feel free to share but we would appreciate a Health Catalyst citation.
Speeding COVID-19 Vaccine Development
The World Economic Forum suggests
the standard vaccination development
process is 10 years.
But, given the immense impact and
transmissibility of COVID-19, pharma-
ceutical companies are working to
accelerate the process and release a
vaccine in less than one year.

While the Food and Drug Administration
(FDA) has rigorous safety and efficacy
standards that pharmaceutical companies
must meet before releasing a vaccine for
public use, COVID-19 has forced a change
in the rules in order to expedite the process.

With a shorter-than-normal time frame,
research teams are under pressure to
understand the novel coronavirus
outbreak and develop a vaccine with
little existing data or research.
Pharmaceutical companies and health
systems alike need the latest population-
based research to keep up with the ever-
changing nature of the virus as they
develop a vaccine and care for patients.

In the past, pharmaceutical companies
have relied on claims data as the main
data source to develop effective
treatments and medication.
However, the static nature of claims
data only gives a snapshot of a patient,
failing to provide the continuing
information that helps research and
care teams keep up with the latest
virus information.

The virus has also caused major
setbacks for clinical trials, now
making patients wait even longer to
receive experimental treatment for
other diseases.
Hospitals have braced for an
onslaught of critically ill patients,
and researchers have had to shelve
clinical trials for other illnesses, all
in response to COVID-19.

Agencies and clinical-trial funders have
shown remarkable flexibility throughout
the pandemic.
However, research teams need access
to near real-time data and insights from
the frontlines to assess the long-term
effects of COVID-19 on clinical trials and
get back on track as soon as possible.

To overcome the lack of data and
information about COVID-19, health
systems are constantly tracking and
recording new data about the virus.
Now the primary source of information—
de-identified COVID-19 patient data
from health systems across the
country—is an imperative to creating a
vaccine and getting life back to normal.

A Comprehensive National Data Set and Registry
Even though there is no historical COVID-19
patient data, pharmaceutical companies can
still leverage comprehensive data for vaccine
development and clinical trial processes.

The Touchstone® for COVID-19 National Data
Sets and Registry allows pharmaceutical
companies to access de-identified patient data
from more than 80 million patients across the
United States (Figure 1), as well as three
national data sources (Johns Hopkins
University, The New York Times, and
The COVID Tracking Project).
Now, pharmaceutical companies can
tap into a breadth of data to conduct
population-based research.

COVID-19 National Registry as of August 2, 2020
Figure 1. States with COVID-19 patient data in Touchstone representing 21 health systems.

Partnering with Health Catalyst bridges
gaps in health data with an ecosystem that
spans hospitals, academic medical centers
(AMCs), and research institutions across
the United States.
With unparalleled access to large sums of
clinical data, coupled with support and
expertise from Health Catalyst leaders to
develop real-world insights and evidence,
pharmaceutical companies can rely on
added bench strength and up-to-date
information from a comprehensive
COVID-19 registry.

The Touchstone COVID-19 National Data Set and Registry goes beyond
data, enabling research in unique ways:
Providing access to a network of healthcare organizations (hospitals, AMCs,
and research institutions) resources, including patients (for clinical trial
recruitment and testing), providers, and researchers.
Fostering collaboration with health experts about standard-of-care practices
to understand how to change and improve clinical care.
Discovering deeper insights and connections that go beyond the data (e.g.,
understanding firsthand how data translates to frontline clinical practice).
Testing and implementing new tools (e.g., a prediction tool) at the point of
care to identify opportunities to improve clinical care.
>
>
>
>

Insights and Research: The Bedrock for
Pharmaceutical Progress and Developments
Because knowledge about COVID-19 is
continually evolving, the need for population-
based research at a national scale is critical.
The most effective population-based research
includes the latest, point-of-care data that
development teams can leverage to steer
research and development.
Reliable, actionable insights—rather than
static, outdated data—allows pharmaceutical
organizations to maximize resources in clinical
trials, shift direction as the virus changes, and
avoid wasting precious resources.

The COVID-19 patient data and population-
based research also benefits pharmaceutical
companies primarily focused on clinical trials.
For example, patients who contract the virus
while participating in unrelated clinical trials
could steer the outcomes of that trial to
misleading endpoints.

Reliable, accurate insights can help
clinical trials stay on track in geographic
areas that are recovering from COVID-
19 and progress to the planning phase
of the COVID-19 framework (Prepare,
Prevent, Recover, Plan).

Getting Research and Development Back on
Track with COVID-19 Patient Data
COVID-19 also impacts the recruitment
process for clinical trials.
For example, a lack of understanding
about the virus makes it difficult to recruit
patients to test new medications that
might react negatively with the virus.

With access to a wealth of continuing point-
of-care data sets across multiple populations,
pharmaceutical companies will more quickly
understand the virus as it evolves and take
this information into account for existing and
future clinical trials.

Additionally, COVID-19 research will
reveal insights that open the door to
future collaboration between health
systems and pharmaceutical companies.
As COVID-19 research and insights
reveal clinical practice trends, research
teams can use this information to
connect with health systems after the
pandemic to review trends and
opportunities to improve care or
develop new treatments.

Three Critical Components for Pharmaceutical Companies
During COVID-19: Insights, Expertise, and Research
COVID-19 presents seemingly endless
unknowns to pharmaceutical companies,
health systems, providers, and patients.
These uncertainties can complicate an
already complex environment and stall
research efforts.

The Touchstone for COVID-19: National
Data Sets and Registry offers near real-
time patient data with outcomes analysis
and clinical trials analysis, so research
teams can stay up to date with, and
adapt to, the virus.

This comprehensive, population-based
research data benefits pharmaceutical
companies—both research-focused and
clinical trial-focused—by providing de-
identified patient data from more than 80
million patients throughout the United States,
integrated with three national data sources.

The registry allows research
pharmaceutical teams to focus on
research and development of the
COVID-19 vaccine and conducting
clinical trials.
With around-the-clock access to the
most recent and complete data sets,
pharmaceutical companies are
prepared to battle the coronavirus
with data-informed research and
prepare for future healthcare
unknowns.

Published Research:
COVID-19 Reinfection Analysis
Federated Observational Study of Clinical
Therapeutics – Inpatient Famotidine
Stratification of Patients by Tumor Type Using
Molecular Profiling in Real-World Data
>
>
>

For more information:
“This book is a fantastic piece of work”
– Robert Lindeman MD, FAAP, Chief Physician Quality Officer

More about this topic
Link to original article for a more in-depth discussion.
Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development
Using COVID-19 Value Sets for Patient Identification
Sadiqa Mahmood, DDS, MPH, General Manager & Senior VP, Life Sciences Business
Extended Real-World Data: The Life Science Industry’s Number One Asset (Executive Report)
Elia Stupka, PhD, Strategic Advisor
Bridging the Data and Trust Gaps: Why Health Catalyst Entered the Life Sciences Market
Dale Sanders, Chief Technology Officer
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care
Alyssa Antonopoulos, Precision Medicine, Associate Director; Elia Stupka, PhD, Strategic Advisor
Adem Albayrak, VP of Technology, Life Sciences Business
Sadiqa Mahmood, DDS, MPH, General Manager & Senior VP, Life Sciences Business
Hospital Capacity Management: How to Prepare for COVID-19 Patient Surges
Jason Jones, PhD, Chief Data Scientist; John Hansmann, MSIE, LFHIMSS, DSHS, Professional Services, VP
Monica Horvath, Strategic Consultant, Health Intelligence & Product Adoption

Sadiqa Mahmood, DDS, MPH is the Senior Vice President and General Manager of the
Life Sciences business at Health Catalyst and contributes to the overall vision and
growth for the company. Sadiqa’s work focuses on identifying and addressing areas of
high unmet need for therapeutic development through application of real-world data.
She is an advisor to several healthcare organizations and global policy makers.
Sadiqa is a dental surgeon and holds a master’s degree in public health from the
Harvard School of Public Health.
Passionate about improving access to care and patient outcomes by leveraging data and healthcare
ecosystem, Sadiqa has spent her career at the intersection of medicine, policy, technology, and
analytics. Previously she led clinical analytics, quality and safety, value-based contracting, and
population health across healthcare organizations, including the Dana-Farber Cancer Institute, Partners
HealthCare System, and Boston Medical Center. Sadiqa has been an advocate of collaborative
learning system in healthcare and has steered cross-industry multi-stakeholder national and global
collaborations to drive healthcare innovation. She joined Health Catalyst in 2019 as SVP of Medical
Affairs. Sadiqa has lived and worked in Asia and UK in addition to the US. She is based in Boston,
Massachusetts. Outside of work, she is a Formula 1 fan and race as a member of a local team.
Other Clinical Quality Improvement Resources
Click to read additional information at www.healthcatalyst.com
Sadiqa Mahmood, DDS, MPH

Other Clinical Quality Improvement Resources
Click to read additional information at www.healthcatalyst.com
Health Catalyst is a mission-driven data warehousing, analytics and outcomes-improvement
company that helps healthcare organizations of all sizes improve clinical, financial, and operational
outcomes needed to improve population health and accountable care. Our proven enterprise data
warehouse (EDW) and analytics platform helps improve quality, add efficiency and lower costs in
support of more than 65 million patients for organizations ranging from the largest US health system
to forward-thinking physician practices.
Health Catalyst was recently named as the leader in the enterprise healthcare BI market in
improvement by KLAS, and has received numerous best-place-to work awards including Modern
Healthcare in 2013, 2014, and 2015, as well as other recognitions such as “Best Place to work for
Millenials, and a “Best Perks for Women.”

Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development

Similar to Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development (20)

More from Health Catalyst

More from Health Catalyst (20)

Recently uploaded

Recently uploaded (20)

Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development